**Lipoproteins and Apolipoproteins of the Ageing Eye**

Edward Loane

354 Lipoproteins – Role in Health and Diseases

325-330.

Transplant 14: 613-622.

Proc 40: 2925-2926.

recipients. Transplantation 58: 245-247.

liver transplant in humans. Transpl Int 19: 389-395.

prevention. Transplantation 82: 603-611.

[85] Baiocchi L, Angelico M, De Luca L, Ombres D, Anselmo A, et al. (2006) Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after

[86] Hulzebos CV, Wolters H, Plosch T, Kramer W, Stengelin S, et al. (2003) Cyclosporin a and enterohepatic circulation of bile salts in rats: decreased cholate synthesis but

[87] Toussaint C, Kinnaert P, Vereerstraeten P (1988) Late mortality and morbidity five to

[88] Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS (2004) Treatment of

[89] Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, et al. (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163: 553-564. [90] Ojo AO (2006) Cardiovascular complications after renal transplantation and their

[91] Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, et al. (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre,

[92] Blum A, Shamburek R (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203:

[93] Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, et al. (2006) Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and

[96] Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ (1995) Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung

[97] Stapleton DD, Mehra MR, Dumas D, Smart FW, Milani RV, et al. (1997) Lipid-lowering therapy and long-term survival in heart transplantation. Am J Cardiol 80: 802-805. [98] Boissonnat P, Salen P, Guidollet J, Ferrera R, Dureau G, et al. (1994) The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant

[99] Suchy D, Labuzek K, Stadnicki A, Okopien B Ezetimibe--a new approach in

[100] Yoon HE, Song JC, Hyoung BJ, Hwang HS, Lee SY, et al. (2009) The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal

[101] Lopez V, Gutierrez C, Gutierrez E, Sola E, Cabello M, et al. (2008) Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia. Transplant

endothelial dysfunction after renal transplantation. Transplantation 82: 771-778. [94] Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-627. [95] Asberg A (2003) Interactions between cyclosporin and lipid-lowering drugs:

increased intestinal reabsorption. J Pharmacol Exp Ther 304: 356-363.

eighteen years after kidney transplantation. Transplantation 45: 554-558.

hyperlipidemia in cardiac transplant recipients. Am Heart J 148: 200-210.

randomised, placebo-controlled trial. Lancet 361: 2024-2031.

implications for organ transplant recipients. Drugs 63: 367-378.

hypercholesterolemia management. Pharmacol Rep 63: 1335-1348.

transplant recipients. Korean J Intern Med 24: 233-237.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/45985
